Compare NAT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAT | TBPH |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 914.8M | 1.0B |
| IPO Year | 1997 | 2013 |
| Metric | NAT | TBPH |
|---|---|---|
| Price | $4.98 | $13.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.25 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 5.2M | 793.5K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 9.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.88 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $56.53 | $70.90 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $525.49 | ★ $15.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.13 | $7.90 |
| 52 Week High | $6.34 | $21.03 |
| Indicator | NAT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 26.47 |
| Support Level | $3.21 | $13.41 |
| Resistance Level | $6.34 | $14.76 |
| Average True Range (ATR) | 0.29 | 0.72 |
| MACD | -0.10 | -0.30 |
| Stochastic Oscillator | 13.22 | 9.79 |
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).